AR052419A1 - Derivados de bencimidazolil n-sustituidos,inhibidores del protooncogen c-kit - Google Patents

Derivados de bencimidazolil n-sustituidos,inhibidores del protooncogen c-kit

Info

Publication number
AR052419A1
AR052419A1 ARP050105014A ARP050105014A AR052419A1 AR 052419 A1 AR052419 A1 AR 052419A1 AR P050105014 A ARP050105014 A AR P050105014A AR P050105014 A ARP050105014 A AR P050105014A AR 052419 A1 AR052419 A1 AR 052419A1
Authority
AR
Argentina
Prior art keywords
8alkyl
optionally substituted
independent
cyclyl
substituted
Prior art date
Application number
ARP050105014A
Other languages
English (en)
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of AR052419A1 publication Critical patent/AR052419A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composiciones farmacéuticas que los contienen, usos como anticancerígenos y bancos combinatorios de benzimidazoles. Reivindicacion 1: Un compuesto represnetadop por la formula (1) o una sal o un N-oxido farmacéuticamente aceptable de la misma, en donde: R1 y R2 son independientemente C0-8 alquil sustituido opcionalmente con un sustituyente heterociclilo; C0-8 alquil sustituido opcionalmente con un halo independiente 1-6, -CONR11R12, -NR13CONR11R12, -NR13CO2R11, -S(O)0-2NR11R12, -NR11S(O)0- 2R12, CN, OH, o sustituyentes del arilo sustituido opcionalmente; -C0-8alquil-C3-8cicloalquil; -C0-8alquil-O-C0-8alquil-, -C0-8alquil- N(C0-8alquil)(C0-8alquil), -C0-8alquil-S(O)0-2-C0-8alquil-; o heterociclilo sustituido opcionalmente con ciclilo, C0-8alquil independiente 1-4, o sustituyentes del ciclilo sustituido; o R1 y R2, tomados juntos con el N al cual se encuentran unidos, forman un grupo heterocíclico, sustituido opcionalmente con grupos C0-8alquil, -C0-8alquil-O-C0-8alquil-, -C0- 8alquil-arilo independientes 1-4, o grupos -C0-8alquil-heteroarilo, siempre que el grupo heterocíclico que se forme no sea piperazina; R3 es un grupo arilo o hetarilo, sustituido opcionalmente con C0-8alquil, C0-8alquil-ciclil, halo, OH, -NR31S(O)0- 2R32, -(O)0-2NR31R32, -NR31COR32, -NR31CONR32R33, - CONR31R32, S(O)0-2R31, O-arilo, -O-hetarilo, NO2, CN, CF3, OCF3, OCHF2; independiente 1-4; R11, R12, R13, R31, R32, y R33 son cada uno independientemente C0-8alquil sustituido opcionalmente con un sustituyente heterociclilo, C0-8alquil sustituido opcionalmente con un sustituyente halo -CON(C0-8alquil)(C0-8alquil), -N(C0-8alquil)CON(C0-8alquil)(C0-8alquil), -N(C0-8alquil)CO2(C0-8alquil), S(O) 0-2N(C0-8alquil)(C0-8alquil), -NR11S(O)0-2(C0- 8alquil), CN, OH, independiente 1-6, o sustituyentes del arilo sustituido opcionalmente; -C0-8alquil-C3-8cicloalquil; -C0-8alquil-O-C0-8alquil-, -C0-8alquil-N(C0-8alquil)(C0-8alquil), -C0-8alquil-S(O)0-2-C0-8alquil-; o heterociclilo sustituido opcionalmente con ciclilo, C0-8alquil independiente 1-4, o sustituyentes del ciclilo sustituido; y siempre que R3 no sea un grupo tetrazolilo, 5-pirimidinilo, o 4-bifenilo.
ARP050105014A 2004-12-01 2005-11-30 Derivados de bencimidazolil n-sustituidos,inhibidores del protooncogen c-kit AR052419A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63243204P 2004-12-01 2004-12-01

Publications (1)

Publication Number Publication Date
AR052419A1 true AR052419A1 (es) 2007-03-21

Family

ID=36128376

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105014A AR052419A1 (es) 2004-12-01 2005-11-30 Derivados de bencimidazolil n-sustituidos,inhibidores del protooncogen c-kit

Country Status (12)

Country Link
US (1) US7419995B2 (es)
EP (1) EP1831206B1 (es)
JP (1) JP2008521903A (es)
KR (1) KR20070086865A (es)
CN (1) CN101193867A (es)
AR (1) AR052419A1 (es)
AT (1) ATE521604T1 (es)
AU (1) AU2005312028A1 (es)
BR (1) BRPI0518794A2 (es)
CA (1) CA2589770A1 (es)
TW (1) TW200633704A (es)
WO (1) WO2006060381A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442709B2 (en) * 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
ES2330468T3 (es) * 2005-04-13 2009-12-10 Neurosearch A/S Derivados de benzimidazol y su uso para modular el complejo del receptor gabaa.
US7776900B2 (en) * 2005-04-19 2010-08-17 Neurosearch A/S Benzimidazole derivatives and their use for modulating the GABAAreceptor complex
KR20080077620A (ko) * 2005-12-05 2008-08-25 뉴로서치 에이/에스 벤즈이미다졸 및 ｇａｂａａ 수용체 복합체를 조절하기위한 이의 용도
TWI391381B (zh) * 2006-03-24 2013-04-01 Neurosearch As 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途
AU2007337895C1 (en) * 2006-12-22 2014-07-31 Astex Therapeutics Limited Tricyclic amine derivatives as protein tyrosine kinase inhibitors
JP5442448B2 (ja) * 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド Ｆｇｆｒインヒビターとしての二環式ヘテロ環式化合物
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) * 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
US20110030037A1 (en) * 2009-07-07 2011-02-03 Vadim Olshansky Zone migration in network access
WO2012131501A1 (en) * 2011-03-28 2012-10-04 Glenmark Pharmaceuticals S.A. Substituted benzimidazole compounds as cot kinase inhibitors
UA111382C2 (uk) * 2011-10-10 2016-04-25 Оріон Корпорейшн Інгібітори протеїнкінази
CN103254134B (zh) * 2012-06-29 2015-09-02 苏州大学 一种多取代咪唑的合成方法
US9790188B2 (en) 2013-03-15 2017-10-17 Whitehead Institute For Biomedical Research Benzimidazole derivatives and uses thereof
CN103254136B (zh) * 2013-05-30 2015-03-25 苏州大学 一种制备四[4-(1-咪唑基)苯基]甲烷的方法
CN103497179B (zh) * 2013-09-26 2015-03-25 郑州大学 含苯并咪唑结构单元的嘧啶衍生物及其制备方法和用途
MX2018000880A (es) * 2015-07-20 2018-08-24 Genzyme Corp Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r).
WO2018112140A1 (en) * 2016-12-15 2018-06-21 Ariad Pharmaceuticals, Inc. Benzimidazole compounds as c-kit inhibitors
CN108754141B (zh) * 2018-08-22 2020-12-08 中国科学院上海有机化学研究所 一种萃取有机相及其应用
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4267573A1 (en) 2020-12-23 2023-11-01 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
BE788751A (fr) 1971-09-13 1973-01-02 Teijin Ltd Membranes polymeres permselectives
GB8610980D0 (en) 1986-05-06 1986-06-11 Ici America Inc Heterocyclic fused tricyclic compounds
US5814651A (en) 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
AU685881B2 (en) 1994-02-10 1998-01-29 Pfizer Inc. 5-heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
US6001866A (en) 1995-10-05 1999-12-14 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5972980A (en) 1995-10-05 1999-10-26 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US6548524B2 (en) * 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
EP0846689B1 (en) 1996-12-09 2004-01-14 Pfizer Inc. Benzimidazole compounds
US6414008B1 (en) 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
BR9810456A (pt) 1997-06-27 2001-09-25 Fujisawa Pharmaceutical Co Composto de sulfonamida, método para sua obtenção e seu uso farmacêutico
US5990146A (en) * 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
US6534503B1 (en) 1998-04-28 2003-03-18 Lion Bioscience Ag Melanocortin receptor-3 ligands to treat sexual dysfunction
BR9912571A (pt) 1998-07-28 2001-11-20 Nihon Nohyaku Co Ltd Derivado de diamida de ácido dicarboxìlicoheterocìclico fundido, herbicida, e, processo paraa utilização de um herbicida
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
US6348032B1 (en) * 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
US6329383B1 (en) 1999-01-25 2001-12-11 Pharmacia Ab 2-amino-5-pyrimidine acetic acid compounds
US6281237B1 (en) 1999-04-02 2001-08-28 Neurogen Corporation N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives
US6816481B1 (en) * 1999-04-09 2004-11-09 Sbc Technology Resources, Inc. Internet caller identification system and method
CO5190696A1 (es) 1999-06-16 2002-08-29 Smithkline Beecham Corp Antagonistas de los receptores il-8
AU6762400A (en) 1999-08-12 2001-03-13 Cor Therapeutics, Inc. Inhibitors of factor xa
US6512000B1 (en) 1999-08-20 2003-01-28 Boehringer Ingelheim Pharma Kg Aminocarbonyl-substituted benzimidazoles having tryptase-inhibitory activity
DE19939463A1 (de) 1999-08-20 2001-02-22 Boehringer Ingelheim Pharma Aminocarbonyl-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1085372B1 (en) 1999-09-13 2004-12-22 Eastman Kodak Company Photographic material having improved color reproduction
EP1214330A1 (en) * 1999-09-21 2002-06-19 LION Bioscience AG Benzimidazole derivatives and combinatorial libraries thereof
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
WO2001057019A1 (en) 2000-02-01 2001-08-09 Cor Therapeutics, Inc. INDALONE AND BENZIMIDAZOLONE INHIBITORS OF FACTOR Xa
US20030190714A1 (en) * 2000-03-10 2003-10-09 Roberds Steven L. Human ion channels
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US20020128232A1 (en) 2000-10-12 2002-09-12 Henderson Scott A. Heterocyclic angiogenesis inhibitors
RU2003120061A (ru) 2000-12-07 2004-11-27 Си Ви Терапьютикс, Инк. (Us) Замещенные 1,3,5-триазины и пиримидины в качестве повышающих авса-1 соединений против заболевания коронарной артерии или атеросклероза
CZ20031910A3 (cs) 2000-12-11 2003-12-17 Tularik Inc. Sloučenina s antagonistickými účinky na CXCR3 a farmaceutický postředek
GB0102109D0 (en) 2001-01-26 2001-03-14 Syngenta Ltd Chemical process
JP2004523565A (ja) 2001-03-05 2004-08-05 トランス　テック　ファーマ，インコーポレイテッド 治療因子としてのベンゾイミダゾール誘導体
US20030109714A1 (en) 2001-03-22 2003-06-12 Neil Wishart Transition metal mediated process
WO2002076960A1 (en) 2001-03-22 2002-10-03 Abbott Gmbh & Co. Kg Transition metal mediated process
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
TWI281861B (en) * 2002-01-29 2007-06-01 Sanofi Aventis A pharmaceutical composition comprising SANORG 34006 for treatment and secondary prophylaxis of venous thromboembolic events in patients with deep venous thrombosis
GB2398781B (en) * 2002-05-23 2005-02-02 Cytopia Pty Ltd Kinase inhibitors
AU2002951247A0 (en) * 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
CN1852905A (zh) * 2003-08-21 2006-10-25 Osi制药公司 具有n－取代的苯并咪唑基的c－kit抑制剂

Also Published As

Publication number Publication date
CN101193867A (zh) 2008-06-04
KR20070086865A (ko) 2007-08-27
US20060116402A1 (en) 2006-06-01
WO2006060381A2 (en) 2006-06-08
EP1831206A2 (en) 2007-09-12
WO2006060381A3 (en) 2006-12-28
TW200633704A (en) 2006-10-01
EP1831206B1 (en) 2011-08-24
CA2589770A1 (en) 2006-06-08
ATE521604T1 (de) 2011-09-15
US7419995B2 (en) 2008-09-02
JP2008521903A (ja) 2008-06-26
BRPI0518794A2 (pt) 2008-12-09
AU2005312028A1 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
AR052419A1 (es) Derivados de bencimidazolil n-sustituidos,inhibidores del protooncogen c-kit
AR059338A1 (es) N-fenilbenzotriazolilo como inhibidores de c-kit
PE20161405A1 (es) Analogos de cortistatina y sintesis y usos de los mismos
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
PE20171057A1 (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
AR082029A1 (es) Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt
AR091272A1 (es) Pirazolopirimidona y pirazolopiridona como inhibidores de tanquirasa
PE20141827A1 (es) Inhibidores de proteinas quinasas
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR076067A1 (es) Composiciones y metodos para modular la senda de senalizacion de wnt
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
PE20040189A1 (es) Pirimidina y piridina biciclicos como inhibidores de p38 quinasa
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
AR051294A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
ES2640911T3 (es) Cicloalquilnitrilpirazolcarboxamidas como inhibidores de la quinasa Janus
AR071867A1 (es) Derivados de quinoxalin y quinolin carboxamida inhibidores de proteinquinasas, proceso para prepararlos, composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento de trastornos proliferativos benignos y malignos.
AR078045A1 (es) Derivados de pirimidina, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer
ES2570127T3 (es) Compuestos y composiciones como inhibidores de la proteína quinasa
AR067838A1 (es) Compuestos pirrolicos, composiciones farmaceuticas que los contienen y usos
AR075510A1 (es) Inhibidores del virus de la hepatitis c
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
AR057989A1 (es) Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas
AR111850A1 (es) Trifluorometiloxadiazoles sustituidos para combatir hongos fitopatógenos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal